## (19) World Intellectual Property Organization

International Bureau





(43) International Publication Date 22 September 2005 (22.09.2005)

**PCT** 

## (10) International Publication Number WO 2005/087759 A1

- (51) International Patent Classification<sup>7</sup>: C07D 401/06, 215/56, A61K 31/47, A61P 31/18
- (21) International Application Number:

PCT/US2005/008202

- (22) International Filing Date: 9 March 2005 (09.03.2005)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

60/552,423

10 March 2004 (10.03.2004) US

- (71) Applicant (for all designated States except US): THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY OF THE DEPARTMENT OF HEALTH AND HUMAN SERVICES [US/US]; National Institutes of Health Office of Technology Transfer, Suite 325, 6011 Executive Boulevard, Rockville, MD 20852-3804 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): DI SANTO, Roberto [IT/IT]; Via Dei Panfili, 108, I-00121 Rome (IT). POMMIER, Yves [US/US]; 8102 Maple Ridge Road, Bethesda, MD 20814 (US). MARCHAND, Christophe [FR/US]; 9823 Bristol Square Lane, Apt. 304, Bethesda, MA 20814 (US). ARTICO, Marino [IT/IT]; Via Cesare Bazzani, 192, I-00128 Rome (IT). COSTI, Roberta [IT/IT]; Via dei Panfili, 108, I-00121 Rome (IT).

- (74) Agent: RUPERT, Wayne, W.; Klarquist Sparkman, LLP, Suite 1600, One World Trade Center, 121 Southwest Salmon Street, Portland, OR 97204 (US).
- (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

## **Declaration under Rule 4.17:**


of inventorship (Rule 4.17(iv)) for US only

## Published:

- with international search report
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: QIUNOLIN-4-ONES AS INHIBITORS OF RETROVIRAL INTEGRASE FOR THE TREATMENT OF HIV, AIDS AND AIDS RELATED COMPLEX (ARC)



(57) Abstract: Novel quinoline inhibitors of retroviral integrase, particularly HIV-1 integrase. The quinoline inhibitors are oxoquinolines of the following formula (I) that can be used for preventing or treating AIDS or HIV infection in a subject. Wherein Z is selected from -C(O)OR<sub>2</sub> then at least one of  $R_3$ ,  $R_4$ ,  $R_5$  or  $R_6$  is -C(O)CH<sub>2</sub>C(O)X and wherein R1, R2, R3, R5, R6 or X are as disclosed herein.